2021
Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project
Bennett JC, Hetrich MK, Garcia Quesada M, Sinkevitch JN, Deloria Knoll M, Feikin DR, Zeger SL, Kagucia EW, Cohen AL, Ampofo K, Brandileone MC, Bruden D, Camilli R, Castilla J, Chan G, Cook H, Cornick JE, Dagan R, Dalby T, Danis K, de Miguel S, De Wals P, Desmet S, Georgakopoulou T, Gilkison C, Grgic-Vitek M, Hammitt LL, Hilty M, Ho PL, Jayasinghe S, Kellner JD, Kleynhans J, Knol MJ, Kozakova J, Kristinsson KG, Ladhani SN, MacDonald L, Mackenzie GA, Mad’arová L, McGeer A, Mereckiene J, Morfeldt E, Mungun T, Muñoz-Almagro C, Nuorti JP, Paragi M, Pilishvili T, Puentes R, Saha SK, Sahu Khan A, Savrasova L, Scott JA, Skoczyńska A, Suga S, van der Linden M, Verani JR, von Gottberg A, Winje BA, Yildirim I, Zerouali K, Hayford K, . Changes in Invasive Pneumococcal Disease Caused by Streptococcus pneumoniae Serotype 1 following Introduction of PCV10 and PCV13: Findings from the PSERENADE Project. Microorganisms 2021, 9: 696. PMID: 33801760, PMCID: PMC8066231, DOI: 10.3390/microorganisms9040696.Peer-Reviewed Original ResearchInvasive pneumococcal diseasePneumococcal conjugate vaccinePneumococcal diseaseIncidence rateSerotype 1Streptococcus pneumoniae serotype 1Mixed-effects Poisson regressionInfant immunization programIntroduction of PCV10Pneumococcal serotype replacementIncidence rate ratiosIPD surveillance dataYears of ageIPD incidenceSerotype replacementLinear mixed-effects regressionConjugate vaccineBurden countriesImmunization programsMixed-effects regressionImportant causePoisson regressionSurveillance dataRate ratioPCV10/13
2020
Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts
Lapidot R, Shea KM, Yildirim I, Cabral HJ, Pelton SI, Health T. Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts. Pathogens 2020, 9: 396. PMID: 32455770, PMCID: PMC7281000, DOI: 10.3390/pathogens9050396.Peer-Reviewed Original ResearchPneumococcal conjugate vaccineIPD casesIncidence rate ratiosIPD incidencePCV-13Disease characteristicsSerotype 3 invasive pneumococcal diseaseInvasive pneumococcal disease incidenceImpact of PCV13Presence of comorbiditiesInvasive pneumococcal diseasePneumococcal disease incidenceUniversal childhood immunizationWaning of immunityPassive surveillance systemPCV13 dosePCV13 introductionVaccine effectivenessConjugate vaccineMassachusetts childrenPneumococcal diseaseClinical syndromeChildhood immunizationIncidence ratePCV13
2018
1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease
Yildirim I, Little B, Shea K, Pelton S, Massachusetts M. 1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease. Open Forum Infectious Diseases 2018, 5: s441-s442. PMCID: PMC6253418, DOI: 10.1093/ofid/ofy210.1261.Peer-Reviewed Original ResearchInvasive pneumococcal diseaseStreptococcus pneumoniaeIPD casesPneumococcal diseaseVaccine serotypesIncidence of IPDCommon clinical presentationIntroduction of PCV13Pneumococcal conjugate vaccineOverall mortality rateChildhood immunization scheduleSickle cell diseaseYears of ageEnhanced surveillance systemIPD incidenceCommon comorbiditiesConjugate vaccineMassachusetts childrenClinical presentationImmunization scheduleCurrent epidemiologyCNS diseaseHematologic malignanciesCell diseaseClinical data
2017
Impact of PCV13 on Serotype 3 Invasive Pneumococcal Disease and Nasopharyngeal Carriage in Massachusetts’ Children
Lapidot R, Shea K, Little B, Yildirim I, Pelton S. Impact of PCV13 on Serotype 3 Invasive Pneumococcal Disease and Nasopharyngeal Carriage in Massachusetts’ Children. Open Forum Infectious Diseases 2017, 4: s467-s467. PMCID: PMC5631065, DOI: 10.1093/ofid/ofx163.1194.Peer-Reviewed Original ResearchPresence of comorbiditiesIPD casesPCV13 implementationYears of ageClinical syndromeSpeaker honorariaNP carriageNasopharyngeal carriageSerotype 3 invasive pneumococcal diseaseInvasive pneumococcal disease incidenceAge distributionEffectiveness of PCV13Impact of PCV13US census estimatesInvasive pneumococcal diseasePneumococcal disease incidenceAnnual incidence rateActive Surveillance NetworkAnnual prevalence rateIPD incidenceMerck vaccinePCV13 dosePneumococcal diseaseVaccination statusVaccine serotypesInvasive Pneumococcal Disease in Massachusetts Children 6 Years Following Introduction of PCV13
Yildirim I, Little B, Pelton S. Invasive Pneumococcal Disease in Massachusetts Children 6 Years Following Introduction of PCV13. Open Forum Infectious Diseases 2017, 4: s67-s67. DOI: 10.1093/ofid/ofx162.159.Peer-Reviewed Original ResearchInvasive pneumococcal diseaseYears of ageNonvaccine serotypesSpeaker honorariaStreptococcus pneumoniaePneumococcal diseaseVaccine serotypesIncidence of IPDImplementation of PCV13Common clinical presentationIntroduction of PCV13Overall mortality rateChildhood immunization scheduleChildren 6 yearsProportion of casesMA childrenEnhanced surveillance systemIPD incidenceMerck vaccineIPD casesConjugate vaccinePCV13 eraClinical presentationComorbid conditionsImmunization schedule
2010
Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease
Yildirim I, Hanage WP, Lipsitch M, Shea KM, Stevenson A, Finkelstein J, Huang SS, Lee GM, Kleinman K, Pelton SI. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine 2010, 29: 283-288. PMID: 21029807, PMCID: PMC3139683, DOI: 10.1016/j.vaccine.2010.10.032.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseInvasive capacityPneumococcal diseaseIncidence of IPDNew pneumococcal conjugate vaccinesPneumococcal conjugate vaccineSterile body sitesStreptococcus pneumoniae serotypesCarriage serotypesNasopharyngeal acquisitionNP carriagePCV eraReplacement serotypesIPD incidenceRespiratory seasonsConjugate vaccineMassachusetts childrenCarriage prevalenceCommon serotypesPneumoniae serotypesOngoing surveillanceEnhanced surveillanceBody sitesPersistent reductionSerotype X